Search Results - S. Leboulleux

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit

    Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit by L. J. Wirth, C. Durante, D. J. Topliss, E. Winquist, E. Robenshtok, H. Iwasaki, M. Luster, R. Elisei, S. Leboulleux, M. Tahara

    Published 2023-03-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer

    A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer by M. S. Brose, Yu. Panaseykin, B. Konda, C. de la Fouchardiere, B. G.M. Hughes, A. G. Gianoukakis, Y. J. Park, I. Romanov, M. K. Krzyzanowska, S. Leboulleux, T. A. Binder, C. Dutcus, R. Xie, M. H. Taylor

    Published 2022-04-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: